OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's technology and team into OpenAI's Rosalind AI model and Rosalind Workbench, tools designed to support life sciences research and experiment planning. This move strengthens OpenAI's position in the pharmaceutical AI sector, with notable customers like Moderna and Novo Nordisk already using Rosalind. The deal reflects a trend where major AI labs expand into key industries by absorbing innovative startups rather than competing directly.
Moderna shares are trading at USD 241.50 with a 1-day gain of 6.44% as of Oct 21, 2026 03:43 WIB on Pluang. Novo Nordisk's stock price is USD 39.31, up 2.32% for the day, reflecting steady investor interest. The typical hold time for Novo Nordisk on Pluang is 117 days, indicating a longer-term investment horizon among users.
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
